Back to Journals » Patient Preference and Adherence » Volume 10

Using qualitative research to facilitate the interpretation of quantitative results from a discrete choice experiment: insights from a survey in elderly ophthalmologic patients

Authors Vennedey V, Danner M, Evers S, Fauser S, Stock S, Dirksen C, Hiligsmann M

Received 30 November 2015

Accepted for publication 2 February 2016

Published 3 June 2016 Volume 2016:10 Pages 993—1002

DOI https://doi.org/10.2147/PPA.S101584

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Doris Leung

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen

Vera Vennedey,1 Marion Danner,1 Silvia MAA Evers,2,3 Sascha Fauser,4 Stephanie Stock,1 Carmen D Dirksen,5 Mickaël Hiligsmann2

1Institute for Health Economics and Clinical Epidemiology, Cologne University Hospital, Cologne, Germany; 2Department of Health Services Research, School for Primary Care and Public Health (CAPHRI), Maastricht University, Maastricht, the Netherlands; 3Department of Public Mental Health, Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, the Netherlands; 4Department of Vitreo-Retinal Surgery, Center of Ophthalmology, Cologne University Hospital, Cologne, Germany; 5Department of Clinical Epidemiology and Medical Technology Assessment, CAPHRI, University Hospital Maastricht, Maastricht, the Netherlands

Background: Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in industrialized countries. Currently, mainly three treatment options are available, which are all intravitreal injections, but differ with regard to the frequency of injections needed, their approval status, and cost. This study aims to estimate patients’ preferences for characteristics of treatment options for neovascular AMD.
Methods: An interviewer-assisted discrete choice experiment was conducted among patients suffering from AMD treated with intravitreal injections. A Bayesian efficient design was used for the development of 12 choice tasks. In each task patients indicated their preference for one out of two treatment scenarios described by the attributes: side effects, approval status, effect on visual function, injection and monitoring frequency. While answering the choice tasks, patients were asked to think aloud and explain the reasons for choosing or rejecting specific characteristics. Quantitative data were analyzed with a mixed multinomial logit model.
Results: Eighty-six patients completed the questionnaire. Patients significantly preferred treatments that improve visual function, are approved, are administered in a pro re nata regimen (as needed), and are accompanied by bimonthly monitoring. Patients significantly disliked less frequent monitoring visits (every 4 months) and explained this was due to fear of deterioration being left unnoticed, and in turn experiencing disease deterioration. Significant preference heterogeneity was found for all levels except for bimonthly monitoring visits and severe, rare eye-related side effects. Patients gave clear explanations of their individual preferences during the interviews.
Conclusion: Significant preference trends were discernible for the overall sample, despite the preference heterogeneity for most treatment characteristics. Patients like to be monitored and treated regularly, but not too frequently or infrequently. The results of our qualitative research facilitated the interpretation of the quantitative data collected in this study.

Keywords: discrete choice experiment, patient preferences, qualitative research, age related macular degeneration, intravitreal injection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]